• Users Online: 483
  • Print this page
  • Email this page
Year : 2022  |  Volume : 65  |  Issue : 6  |  Page : 319-327

Leonurine suppresses prostate cancer growth in vitro and in vivo by regulating miR-18a-5p/SLC40A1 axis

Department of Urology, Changzhou Cancer (Fourth People's) Hospital, Changzhou, China

Correspondence Address:
Dr. Bin Liang
Department of Urology, Changzhou Cancer (Fourth People's) Hospital, No. 68 Honghe Road, Xinbei District, Changzhou, Jiangsu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0304-4920.365459

Rights and Permissions

Prostate cancer is a leading cause of cancer-associated death in males. Leonurine (Leo) is a pleiotropic anti-tumor agent isolated from traditional Chinese herb that was used in gynecologic treatments. However, its pharmacological effect against prostate cancer progression remains unclear. Here, we showed that Leo dose dependently inhibited prostate cancer cell proliferation, promoted cell apoptosis, and induced cell cycle arrest. Moreover, we noticed that miR-18a-5p was downregulated and the solute carrier family 40 member 1 (SLC40A1) is upregulated by Leo treatment. SLC40A1 knockdown by siRNA abrogated the inhibitory effect of Leo on prostate cancer progression. Notably, Leo also significantly inhibited prostate cancer progression in a subcutaneous xenograft tumor mouse model in vivo. This study further unveiled the mechanism by which Leo inhibited prostate cancer progression, which provides a promising potential for its future clinical application.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal